The HTRA1 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population engineered for loss-of-function studies of the HTRA1 gene in a human hepatic adenocarcinoma background. This polyclonal knockout format provides a heterogeneous pool of edited cells, enabling robust assessment of gene function without clonal selection bias. The CRISPR-mediated disruption of HTRA1 abolishes its serine protease activity, yielding a versatile cellular model for dissecting HTRA1??s roles in extracellular matrix regulation and tumor suppression.
The parental SK-HEP-1 cell line was originally derived from the ascitic fluid of a patient with liver adenocarcinoma and displays an adherent, epithelial-like morphology. SK-HEP-1 cells co-express epithelial and endothelial markers, making them a widely utilized in vitro model for hepatocellular carcinoma, tumor invasion, and metastasis research. This host line also supports studies of hepatic drug metabolism, providing a clinically relevant platform for pharmacological investigations.
HTRA1 encodes an extracellular serine protease that proteolytically degrades multiple ECM components, including fibronectin and decorin, and modulates TGF-??/BMP signaling by cleaving latent TGF-?? binding proteins (LTBPs). Its activity is regulated by upstream factors such as TGF-??1, oxidative stress, hypoxia, and p53, and it downstream targets key mediators like SMAD proteins, MMP-2, MMP-9, and IGFBP-5. HTRA1 also interacts with alpha-2-macroglobulin and PDZK1, positioning it as a critical node in ECM remodeling and signal transduction networks.
In the SK-HEP-1 background, HTRA1 knockout impairs the degradation of ECM substrates and disrupts the processing of latent TGF-?? complexes, leading to deregulated TGF-?? signaling. This molecular perturbation is associated with altered cell adhesion, enhanced migration, and increased tumorigenic potential, mirroring aspects of hepatocellular carcinoma progression where HTRA1 downregulation is observed. Consequently, this knockout model provides a powerful tool for investigating the mechanistic link between HTRA1 loss, TGF-?? pathway aberrations, and liver cancer pathogenesis.
Researchers can employ these polyclonal knockout cells in a variety of experimental settings, including Western blotting for HTRA1 and phosphorylated SMADs, RT-qPCR analysis of TGF-?? target genes, immunofluorescence staining of fibronectin, Transwell migration assays, and Annexin V-based apoptosis detection. Additional applications include TGF-?? luciferase reporter assays, co-immunoprecipitation of HTRA1 with LTBPs, and gelatin zymography to assess MMP activity. This model is also suitable for drug screening campaigns targeting HTRA1-mediated pathways and for mechanistic studies in age-related macular degeneration. For further technical details or assistance with experimental design, please contact Ascent Research.
